Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
Recruiting now
Conditions studied: Ovarian Cancer
In brief
The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. Given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. The aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.
Key facts
- Study ID
- NCT06229522
- Run by
- Centro di Riferimento Oncologico - Aviano
- People needed
- 150
- Starts
- 2023-11-16
- Expected to finish
- 2037-12-31
- Last updated by the study team
- 2024-01-29
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Signed informed consent form;
- Female sex;
- Age ≥18 years;
- Diagnosis of ovarian cancer;
- Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose
You may not qualify if…
- Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments;
- Pregnancy or breast-feeding
- History of concomitant or previous malignancy in the last 5 years
Where it is running
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.